Chapter 14: Substance-Related Disorders

The chapter then examines the neurobiological mechanisms underlying addiction, particularly how various substances interact with the brain's reward pathways by modulating dopaminergic transmission in the nucleus accumbens and ventral tegmental area, essentially hijacking natural reinforcement systems. Specific substance classes receive detailed analysis: alcohol and its withdrawal syndrome requiring careful medical management, stimulants like cocaine and methamphetamine that produce intense dopamine surges followed by severe depletion, opioids including heroin and fentanyl that activate mu receptors and create profound physical dependence, and hallucinogens or dissociative drugs that alter perception and may precipitate psychotic episodes. A critical component addresses the high comorbidity between substance use disorders and psychiatric conditions, recognizing that substances often serve as maladaptive coping mechanisms for underlying anxiety, depression, or trauma, while also recognizing how chronic use can independently generate psychiatric symptoms. The chapter explores evidence-based pharmacological interventions including medication-assisted treatment approaches like methadone and buprenorphine for opioid dependence, naltrexone for relapse prevention across multiple substance classes, benzodiazepines and other agents for managing acute withdrawal, and medications targeting co-occurring psychiatric symptoms. Behavioral and psychosocial interventions complement pharmacotherapy, emphasizing contingency management, cognitive-behavioral approaches, and community reinforcement strategies. The material emphasizes that successful treatment requires integrated approaches addressing both the biological drivers of addiction and the psychological, social, and environmental factors maintaining substance use patterns.